What are the recommended treatment options and considerations for managing hyperthyroidism in a pediatric patient?

Treatment of Pediatric Hyperthyroidism

Methimazole (MMI) should be the first-line treatment for virtually every pediatric patient with hyperthyroidism, started at 0.2-0.5 mg/kg/day (up to 30 mg/day) given once daily, with propylthiouracil contraindicated in children due to unacceptable hepatotoxicity risk. 1

Initial Medical Management

Drug Selection and Dosing

Only methimazole or carbimazole (imidazole derivatives) should be used in children - propylthiouracil carries a 1 in 2,000-4,000 risk of fulminant hepatic failure requiring liver transplantation. 1

Age-based MMI dosing approach:

• Infants: 1.25 mg/day
• 1-5 years: 2.5-5.0 mg/day
• 5-10 years: 5-10 mg/day
• 10-18 years: 10-20 mg/day
• For severe hyperthyroidism (free T4 >70 pmol/L): increase doses by 50-100% 1

Alternatively, weight-based dosing of 0.4-0.8 mg/kg/day for carbimazole (0.3-0.6 mg/kg for thiamazole), with 0.4 mg/kg suitable for moderate disease and 0.8 mg/kg for severe forms. 2

Monitoring Protocol

Baseline testing required:

• Complete blood count with differential
• Liver function tests (bilirubin, transaminases, alkaline phosphatase) 1

Follow-up schedule:

• First 2 weeks, then monthly until TSH normalizes
• Check free T4, free T3, and TSH (not just TSH initially, as some forms predominantly affect T3)
• Once euthyroid: quarterly monitoring 2

Euthyroidism typically achieved within 2-6 weeks. When normalized, reduce MMI dose by 30-50% to minimum effective maintenance (usually 5-15 mg/day). 2

Symptomatic Management

Beta-blockers are recommended for:

• Heart rate >100 bpm
• Severe symptoms (tachycardia, tremor, muscle weakness)
• Dosing: Atenolol 1-2 mg/kg once daily OR Propranolol 1-2 mg/kg in 2-3 divided doses
• Continue for first 2-4 weeks until thyroid hormones normalize 2, 1

Critical Safety Education

Patients and caregivers must immediately stop medication and contact physician if they develop:

• Fever or pharyngitis (agranulocytosis risk - 0.2% incidence)
• Pruritic rash, jaundice, dark urine, light-colored stools
• Arthralgias, abdominal pain, nausea, fatigue 1

Minor side effects (urticaria, rashes, arthralgias) occur in 5-25% of children but are usually transient. 2

Duration and Definitive Treatment Decisions

Initial Treatment Course

Treat with MMI for 1-2 years, then discontinue or reduce dose to assess remission. 1 However, recognize that lasting remission occurs in only a minority of pediatric patients - remission rates are approximately:

• After 1 year: 10-25%
• After 2 years: 14-26%
• After 4 years: 23-37%
• 30% of those achieving remission will relapse 1

Recent data shows remission rates have declined further, with only 31.1% overall remission and increased relapse rates (15.9% vs 4.6%) in children diagnosed 2010-2019 compared to 2000-2009. 3

When to Consider Definitive Treatment

If remission is not achieved after 1-2 years of MMI therapy, consider radioactive iodine (RAI) or thyroidectomy. 1 Alternatively, continue low-dose MMI as bridge therapy until the child is old enough for definitive treatment, though likelihood of eventual remission remains low. 1

Factors suggesting low remission probability at presentation:

• Prepubertal age (only 17% remission vs 30% in pubertal children)
• Persistent TRAb positivity (normalized in only 18% after 24 months)
• Younger age and anti-TPO positivity associated with later remission 1, 3

Radioactive Iodine Therapy

Age-Based Recommendations

RAI should be avoided in children <5 years old. 1

For ages 5-10 years: RAI acceptable if calculated dose is <10 mCi 1

For ages >10 years: RAI acceptable if activity is >150 μCi/gram of thyroid tissue 1

RAI Administration Protocol

Goal: Induce hypothyroidism (not euthyroidism) to avoid residual partially-irradiated tissue at increased cancer risk. 1

Dosing:

• Administer >150 μCi/gram thyroid tissue in single dose
• For large glands (50-80g): may need 200-300 μCi/gram
• Some centers use fixed dose of ~15 mCi for all children
• Consider surgery for goiters >80g (high risk of underestimating size) 1

Pre-treatment preparation for severe hyperthyroidism:

• If total T4 >20 μg/dL or free T4 >5 ng/dL: pretreat with MMI and beta-blockers until normalized
• Stop MMI 3-5 days before RAI
• Continue beta-blockers until thyroid hormones normalize post-RAI 1

Surgical Management

Thyroidectomy is indicated when:

• Child is too young for RAI (<5 years) and definitive treatment needed
• Patient develops serious allergic reaction to MMI
• Proper surgical expertise unavailable for RAI
• Patient not suitable RAI candidate
• Goiter >80g 1

Critical requirement: Surgery must be performed by high-volume thyroid surgeon with pediatric experience - complication rates are significantly higher in children than adults. 1

Procedure: Near-total or total thyroidectomy recommended 4

Pre-operative Preparation

If MMI cannot be used (e.g., allergic reaction):

• Beta-blockade PLUS
• SSKI (50 mg iodide/drop) 3-7 drops (0.15-0.35 mL) three times daily for 10 days before surgery
• If surgery delayed beyond few weeks: short-course PTU with close monitoring may be considered 1

Important Clinical Pitfalls

Avoid "block and replace" regimen (high-dose MMI + levothyroxine) - meta-analyses show higher adverse event rates with no benefit for relapse prevention. 2, 1

Do not routinely monitor CBCs - agranulocytosis occurs suddenly (95% within first 100 days) and is symptomatic, making routine monitoring ineffective. 1

Do not underestimate treatment duration - children require longer treatment than adults, and TRAb levels persist longer in pediatric patients. 1

Recognize false hyperthyroidism - biotin supplementation (used in metabolic diseases) can cause false laboratory picture of hyperthyroidism due to streptavidin/biotin assay interference. 2